Clinical trials: Age-related Macular Degeneration, open to volunteers
Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD)
MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration.
Age-related macular degeneration (AMD) is the major cause of legal blindness in developed countries. Intermediate AMD represents the most frequent stage.
- Conditions
- Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD), AMD Population - Intermediate or Advanced AMD, AMD and Macular Edema
- Trial name
- MIND-AMD (NCT07847151)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Neovascular Age-Related Macular Degeneration
Extension Study for the Port Delivery System With Ranibizumab (Portal)
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed…
- Trial name
- Portal (NCT03683251)
- Testing
- PDS Implant with Ranibizumab 100 mg/mL
- Where
- 165 sites in United States, Argentina and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Age Related Macular Degeneration (AMD)
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
- Trial name
- ORACLE (NCT05481827)
- Testing
- GT005
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 225 people
- Sponsor
- Gyroscope Therapeutics Limited
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
Dry Age-related Macular Degeneration, Geographic Atrophy
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
- Trial name
- PATCH-AMD (NCT06557460)
- Testing
- Surgical implantation of the CPCB-RPE1 implant
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regenerative Patch Technologies, LLC
Dry Age-related Macular Degeneration
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with…
- Trial name
- NCT06351605
- Testing
- Valeda® Light Delivery System
- Where
- 6 sites in United States, Norway
- Volunteers
- 500 people
- Sponsor
- LumiThera, Inc.
Neovascular Age-related Macular Degeneration (AMD)
Progression Suppression and Retinal Regression in VEGF-resistant AMD
The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy.
- Trial name
- PRESERVE (NCT07005323)
- Testing
- Pars plana vitrectomy
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- PharmaBio Corporation
Neovascular (Wet) Age-Related Macular Degeneration
First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)
This is a first-in-human clinical trial evaluating the safety and tolerability of BETA-TT8 Ophthalmic Gel in people with wet age-related macular degeneration (AMD).
- Trial name
- BEyOND (NCT07766473)
- Testing
- BETA-TT8 ophthalmic gel 3.8% w/v
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Filamon LTD
Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration
Changes in Intraocular Pressure After Intravitreal Injection
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP).
- Conditions
- Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, Retinal Vein Occlusion, Ocular Hypertension
- Trial name
- NCT07826286
- Volunteers
- 50 people
- Sponsor
- Assiut University
Alcohol Use Disorder, Retinal Dystrophies
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner…
- Conditions
- Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa
- Trial name
- NCT06319872
- Testing
- Oral disulfiram
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Rochester
Age Related Macular Degeneration
Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting
Neovascular age-related macular degeneration (nAMD), also called wet AMD, can cause serious vision loss. While anti-VEGF (anti Vascular Endothelial Growth Factor) treatments such as ranibizumab help many patients, about 20 40%…
- Trial name
- M-VIVA (NCT07249216)
- Testing
- Faricimab, Ranibizumab
- Where
- Singapore
- Volunteers
- 117 people
- Sponsor
- Singapore National Eye Centre
Wet Age Related Macular Degeneration
A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
This phase 2 trial is a randomized, double-blind, placebo-controlled, multicenter study in patients with wet AMD to assess the efficacy and safety of NT-101 topical ophthalmic solution (0.20 mM) administered into the study eye…
- Trial name
- NCT07811726
- Testing
- NT-101 ophthalmic solution
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- NexThera Co., Ltd.
Age-related Macular Degeneration
A First-In-Human Study of ARO-033 in Adult Participants
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs) and the safety…
- Trial name
- NCT07662096
- Testing
- ARO-033
- Where
- New Zealand
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Wet Age-related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- SAHARA (NCT07816289)
- Testing
- OLN324, Ranibizumab
- Volunteers
- 400 people
- Sponsor
- Ollin Biosciences, Inc.
Wet Age Related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- MOJAVE (NCT07816315)
- Testing
- OLN324, Aflibercept
- Volunteers
- 500 people
- Sponsor
- Ollin Biosciences, Inc.
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients with GA associated with AMD.
- Trial name
- NCT06659445
- Testing
- ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution
- Where
- 120 sites in United States, Austria and 10 more
- Volunteers
- 324 people
- Sponsor
- ONL Therapeutics
Neovascular Age Related Macular Degeneration(nAMD)
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- ASCEND (NCT07798375)
- Testing
- VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration
- Volunteers
- 244 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Age Related Macular Degeneration
Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
Age-related macular degeneration (AMD) affects 2 million people in France and is the main cause of irreversible blindness in France. All patients initially have an early form of the disease.
- Trial name
- SURViVOR (NCT04697095)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Hospices Civils de Lyon
AMD - Age-Related Macular Degeneration
Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration
This study evaluates whether a low-energy laser treatment called photobiomodulation (PBM) can improve visual function and retinal structure in patients with age-related macular degeneration (AMD) who have reticular pseudodrusen.
- Trial name
- PBM in iAMD (NCT07554690)
- Testing
- Photobiomodulation Therapy
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS